Objective: Epidemiologic studies have reported various results relating coffee to urolithiasis. A meta-analysis of cohort and case-control studies was conducted to pool the relative risk (RR) estimates of the association between coffee and urolithiasis. Methods: Eligible studies were retrieved via both computer searches and review of references. We analyzed abstracted data with random effects models to obtain the summary RR estimates. A dose-response meta-analysis was performed for studies reporting categorical RR estimates for a series of exposure levels. Results: A total of 6 studies (2 cohort and 4 case-control studies) on coffee intake were included in the meta-analysis. The pooled odds ratio (OR) showed a significant influence of the highest coffee consumption (OR = 0.70, 95% confidence interval 0.60-0.82) on the risk of urolithiasis. Coffee exhibited an inverse dose-response relationship with urolithiasis. In stratified analysis, a significant inverse association between coffee and urolithiasis was observed in study design, geographical region and gender subgroup. Conclusions: The overall current literature suggests that coffee intake is associated with a decreased risk of urolithiasis. Further efforts should be made to clarify the underlying biological mechanisms.

Keywords:
Coffee, Urolithiasis, Meta-analysis, Cohort, Case-control
1.
Romero V, Akpinar H, Assimos DG: Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 2010;12:e86-e96.
2.
Scales CD Jr, Smith AC, Hanley JM, Saigal CS: Prevalence of kidney stones in the United States. Eur Urol 2012;62:160-165.
3.
Valdivielso JM, Fernandez E: Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 2006;371:1-12.
4.
Bartoletti R, Cai T, Mondaini N, Melone F, Travaglini F, Carini M, Rizzo M: Epidemiology and risk factors in urolithiasis. Urol Int 2007;79(suppl 1):3-7.
5.
Curhan GC, Willett WC, Rimm EB, Stampfer MJ: Family history and risk of kidney stones. J Am Soc Nephrol 1997;8:1568-1573.
6.
Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A: Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996;155:839-843.
7.
Siener R, Schade N, Nicolay C, von Unruh GE, Hesse A: The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients. J Urol 2005;173:1601-1605.
8.
Ferraro PM, Taylor EN, Gambaro G, Curhan GC: Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol 2013;8:1389-1395.
9.
Nkondjock A: Coffee consumption and the risk of cancer: an overview. Cancer Lett 2009;277:121-125.
10.
Happonen P, Laara E, Hiltunen L, Luukinen H: Coffee consumption and mortality in a 14-year follow-up of an elderly northern Finnish population. Br J Nutr 2008;99:1354-1361.
11.
Ascherio A, Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Rodriguez C, Thun MJ: Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004;160:977-984.
12.
Lindsay J, Laurin D, Verreault R, Hébert R, Helliwell B, Hill GB, McDowell I: Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156:445-453.
13.
van Dam RM, Feskens EJ: Coffee consumption and risk of type 2 diabetes mellitus. Lancet 2002;360:1477-1478.
14.
Wu JN, Ho SC, Zhou C, Ling WH, Chen WQ, Wang CL, Chen YM: Coffee consumption and risk of coronary heart diseases: a meta-analysis of 21 prospective cohort studies. Int J Cardiol 2009;137:216-225.
15.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
16.
Greenland S, Longnecker MP: Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992;135:1301-1309.
17.
Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-826.
18.
Zintzaras E, Ioannidis JP: Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-137.
19.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
20.
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
21.
Safarinejad MR: Adult urolithiasis in a population-based study in Iran: prevalence, incidence, and associated risk factors. Urol Res 2007;35:73-82.
22.
Soucie JM, Coates RJ, McClellan W, Austin H, Thun M: Relation between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epidemiol 1996;143:487-495.
23.
Gasinska A, Gajewska D: Tea and coffee as the main sources of oxalate in diets of patients with kidney oxalate stones. Rocz Panstw Zakl Hig 2007;58:61-67.
24.
Pendse AK, Singh PP: The etiology of urolithiasis in Udaipur (western part of India). Urol Res 1986;14:59-62.
25.
Vahlensieck EW, Bach D, Hesse A, Strenge A: Epidemiology, pathogenesis and diagnosis of calcium oxalate urolithiasis. Int Urol Nephrol 1982;14:333-347.
26.
Massey LK, Sutton RA: Acute caffeine effects on urine composition and calcium kidney stone risk in calcium stone formers. J Urol 2004;172:555-558.
27.
Hirvonen T, Pietinen P, Virtanen M, Albanes D, Virtamo J: Nutrient intake and use of beverages and the risk of kidney stones among male smokers. Am J Epidemiol 1999;150:187-194.
28.
Shuster J, Finlayson B, Scheaffer RL, Sierakowski R, Zoltek J, Dzegede S: Primary liquid intake and urinary stone disease. J Chronic Dis 1985;38:907-914.
29.
Krieger JN, Kronmal RA, Coxon V, Wortley P, Thompson L, Sherrard DJ: Dietary and behavioral risk factors for urolithiasis: potential implications for prevention. Am J Kidney Dis 1996;28:195-201.
30.
Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ: Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol 1996;143:240-247.
31.
Curhan GC, Willett WC, Speizer FE, Stampfer MJ: Beverage use and risk for kidney stones in women. Ann Intern Med 1998;128:534-540.
32.
Goldfarb DS, Fischer ME, Keich Y, Goldberg J: A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int 2005;67:1053-1061.
33.
Dai M, Zhao A, Liu A, You L, Wang P: Dietary factors and risk of kidney stone: a case-control study in southern China. J Ren Nutr 2013;23:e21-e28.
34.
Alvarez Arroyo MV, Traba ML, Rapado A: Hypocitraturia as a pathogenic risk factor in the mixed (calcium oxalate/uric acid) renal stones. Urol Int 1992;48:342-346.
35.
Tungsanga K, Sriboonlue P, Futrakul P, Yachantha C, Tosukhowong P: Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res 2005;33:65-69.
36.
Thamilselvan S, Byer KJ, Hackett RL, Khan SR: Free radical scavengers, catalase and superoxide dismutase provide protection from oxalate-associated injury to LLC-PK1 and MDCK cells. J Urol 2000;164:224-229.
37.
Thamilselvan S, Khan SR: Oxalate and calcium oxalate crystals are injurious to renal epithelial cells: results of in vivo and in vitro studies. J Nephrol 1998;11(suppl 1):66-69.
38.
Holoch PA, Tracy CR: Antioxidants and self-reported history of kidney stones: the National Health and Nutrition Examination Survey. J Endourol 2011;25:1903-1908.
39.
Cämmerer B, Kroh LW: Antioxidant activity of coffee brews. Eur Food Res Technol 2006;223:469-474.
40.
Stalmach A, Mullen W, Nagai C, Crozier A: On-line HPLC analysis of the antioxidant activity of phenolic compounds in brewed, paper-filtered coffee. Braz J Plant Physiol 2006;18:253-262.
41.
Parras P, Martinez-Tome M, Jiménez A, Murcia M: Antioxidant capacity of coffees of several origins brewed following three different procedures. Food Chem 2007;102:582-592.
42.
Bravo L: Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 1998;56:317-333.
43.
Castillo MDd, Gordon MH, Ames JM: Peroxyl radical-scavenging activity of coffee brews. Eur Food Res Technol 2005;221:471-477.
44.
Massey LK: Tea oxalate. Nutr Rev 2000;58:88-89.
45.
Tiselius HG: Aspects on estimation of the risk of calcium oxalate crystallization in urine. Urol Int 1991;47:255-259.
46.
Massey LK, Wise KJ: Impact of gender and age on urinary water and mineral excretion responses to acute caffeine doses. Nutr Res 1992;12:605-612.
47.
Wabner CL, Pak CY: Effect of orange juice consumption on urinary stone risk factors. J Urol 1993;149:1405-1408.
48.
Seltzer MA, Low RK, McDonald M, Shami GS, Stoller ML: Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol 1996;156:907-909.
49.
Kang DE, Sur RL, Haleblian GE, Fitzsimons NJ, Borawski KM, Preminger GM: Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis. J Urol 2007;177:1358-1362; discussion 1362; quiz 1591.
50.
Curhan GC, Willett WC, Rimm EB, Stampfer MJ: A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993;328:833-838.
51.
Taylor EN, Stampfer MJ, Curhan GC: Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004;15:3225-3232.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.